Inari Medical, Inc. (NARI)
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Investigation
07/16/2021
Initial Lawsuit
07/16/2021
Lawsuit Progression
11/23/2021
Investigation regarding RenovaCare’s 2017-2018 paid promotional campaign designed to illegally increase the company’s stock price.
05/28/2021
The U.S. Securities and Exchange Commission announces charges agaisnt RenovaCare and its controlling shareholder Harmel S. Rayat with securities fraud for “intentionally concealing Rayat and the company’s role in promotional activities, including by drafting and issuing a press release that denied their participation in those activities.”
“The SEC’s complaint, filed in federal court in the Southern District of New York, alleges that in July 2017, Rayat arranged, and caused RenovaCare to pay for, a promotional campaign designed to increase the company’s stock price.“
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$2.42 | $2.66 | $-0.24 | -9.02% |
This is a class action on behalf of persons and entities that purchased or otherwise acquired RenovaCare securities between August 14, 2017 and May 28, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that, at the direction of Rayat, RenovaCare engaged in a promotional campaign to issue misleading statements to artificially inflate the Company’s stock price;
(2) that, when the OTC Markets inquired, RenovaCare and Rayat issued a materially false and misleading press release claiming that no director, officer, or controlling shareholder had any involvement in the purported third party’s promotional materials;
(3) that, as a result of the foregoing, the Company’s disclosure controls and procedures were defective;
(4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
11/23/2021
The court issued an order appointing the lead plaintiff and lead counsel.
02/11/2022
This is a federal securities class action on behalf of persons and entities that purchased or otherwise acquired RenovaCare securities between August 14, 2017, and May 28, 2021, inclusive.
Operative complaint
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.